Aeglea BioTherapeutics (NASDAQ: AGLE) will present a corporate overview at BIO Digital from June 8-12, 2020. The presentation will be led by President and CEO Anthony G. Quinn, M.B. Ch.B., Ph.D. It can be accessed on-demand by registered participants and will also be available for download on Aeglea's website. Aeglea is focused on developing human enzyme therapeutics for rare diseases, notably its lead candidate pegzilarginase, currently in a Phase 3 trial for Arginase 1 Deficiency. The company has also received regulatory approval for another treatment, ACN00177, for Homocystinuria.
Aeglea BioTherapeutics (NASDAQ: AGLE) announced a change to its 2020 annual meeting of stockholders due to COVID-19, moving to a virtual format on June 8, 2020, at 9:00 a.m. Central Time. Stockholders must use their control number from proxy cards to attend. Aeglea's lead product, pegzilarginase, is in a pivotal Phase 3 trial for Arginase 1 Deficiency and has received Rare Pediatric Disease and Breakthrough Therapy Designations. The company also received approval for ACN00177 for Homocystinuria treatment.
Summary not available.
Summary not available.
Summary not available.